{"title":"Risk factors for coronary in-stent restenosis in Moroccan patients: a retrospective case-control study.","authors":"Rajaa El Mansouri, Rachida Habbal","doi":"10.14715/cmb/2025.71.8.7","DOIUrl":null,"url":null,"abstract":"<p><p>In-stent restenosis remains a significant challenge in interventional cardiology despite technological advancements. This retrospective case-control study conducted at the University Hospital Center Ibn Rochd in Casablanca (2020-2023) examined risk factors associated with coronary in-stent restenosis in 68 patients equally distributed between restenosis and no-restenosis groups. Diabetes emerged as a powerful predictor of restenosis (RR=4.15, 95% CI [1.05-16.4]), with notable differences in lipid profiles between groups. Restenosis patients exhibited significantly higher LDL cholesterol (2.19 vs. 1.31 mmol/L, p<0.001) and lower HDL levels. Univariate logistic regression identified multiple significant factors, including medication intake duration (OR=1.30, 95% CI [1.09-1.54], p=0.003) and LDL levels (OR=26.7, 95% CI [5.03-141.8], p<0.001). Dual antiplatelet therapy duration differed significantly between groups (p<0.001), while stent characteristics showed no significant differences. Our findings highlight diabetes mellitus as a critical determinant of coronary in-stent restenosis, operating synergistically with specific lipid abnormalities. These results underscore the need for targeted preventive strategies in diabetic patients undergoing percutaneous coronary intervention, including aggressive glycemic control, intensive lipid management, and optimized antiplatelet therapy regimens. The pronounced relationship between diabetes and restenosis emphasizes the importance of individualized approaches to coronary intervention in this high-risk population.</p>","PeriodicalId":520584,"journal":{"name":"Cellular and molecular biology (Noisy-le-Grand, France)","volume":"71 8","pages":"42-47"},"PeriodicalIF":0.0000,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cellular and molecular biology (Noisy-le-Grand, France)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14715/cmb/2025.71.8.7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
In-stent restenosis remains a significant challenge in interventional cardiology despite technological advancements. This retrospective case-control study conducted at the University Hospital Center Ibn Rochd in Casablanca (2020-2023) examined risk factors associated with coronary in-stent restenosis in 68 patients equally distributed between restenosis and no-restenosis groups. Diabetes emerged as a powerful predictor of restenosis (RR=4.15, 95% CI [1.05-16.4]), with notable differences in lipid profiles between groups. Restenosis patients exhibited significantly higher LDL cholesterol (2.19 vs. 1.31 mmol/L, p<0.001) and lower HDL levels. Univariate logistic regression identified multiple significant factors, including medication intake duration (OR=1.30, 95% CI [1.09-1.54], p=0.003) and LDL levels (OR=26.7, 95% CI [5.03-141.8], p<0.001). Dual antiplatelet therapy duration differed significantly between groups (p<0.001), while stent characteristics showed no significant differences. Our findings highlight diabetes mellitus as a critical determinant of coronary in-stent restenosis, operating synergistically with specific lipid abnormalities. These results underscore the need for targeted preventive strategies in diabetic patients undergoing percutaneous coronary intervention, including aggressive glycemic control, intensive lipid management, and optimized antiplatelet therapy regimens. The pronounced relationship between diabetes and restenosis emphasizes the importance of individualized approaches to coronary intervention in this high-risk population.
尽管技术进步,支架内再狭窄仍然是介入心脏病学的重大挑战。这项回顾性病例对照研究于2020-2023年在卡萨布兰卡伊本罗chd大学医院中心进行,研究了68例冠状动脉支架内再狭窄相关的危险因素,这些患者平均分布在再狭窄组和非再狭窄组。糖尿病成为再狭窄的一个强有力的预测因子(RR=4.15, 95% CI[1.05-16.4]),两组之间的脂质谱有显著差异。再狭窄患者LDL胆固醇明显升高(2.19 vs. 1.31 mmol/L, p